Loading people...
Gregory Harriman is a physician, scientist, and Partner at BioAdvance Capital, bringing over 25 years of professional experience to the biopharmaceutical industry. He previously held clinical research and development leadership roles at Johnson & Johnson, Centocor, and IVAX, where he directed the regulatory advancement of therapeutics including the biologic Remicade. Before entering the corporate sector, Harriman built an academic career at the National Institutes of Health and Baylor College of Medicine, securing federal grants while authoring more than 40 scientific publications. He earned his medical degree from the UC San Diego School of Medicine and later served a 30-month federal prison sentence following a 2016 conviction for embezzling funds from a Vermont employer. Today, his professional focus centers on life sciences investments, clinical regulatory strategy, and translational medical research across the broader biotechnology sector.
Gregory Harriman is a distinguished Partner at BioAdvance, a prominent venture capital firm renowned for its strategic investments in the life sciences sector. In his pivotal role, Gregory Harriman is responsible for sourcing, evaluating, and executing investments in groundbreaking companies that are poised to revolutionize healthcare and biotechnology. His work at BioAdvance involves a comprehensive approach, from initial due diligence to active portfolio management, ensuring that promising ventures receive the strategic guidance and capital necessary for success.
Gregory Harriman's investment focus areas are deeply rooted in the expansive and rapidly evolving life sciences landscape. He primarily targets early-stage companies engaged in drug discovery and development, novel therapeutic platforms, medical devices, diagnostics, and digital health solutions. His keen eye for disruptive technologies and innovative scientific approaches allows BioAdvance to identify companies with high growth potential and significant impact on patient care. Harriman is particularly interested in ventures that address unmet medical needs, demonstrate strong scientific foundations, and possess robust intellectual property.
Before joining BioAdvance, Gregory Harriman cultivated a robust career background that provided him with a multifaceted understanding of the life sciences industry. His experience spans various critical areas, including scientific research, business development within biotech startups, and strategic consulting for pharmaceutical companies. This diverse background equips him with a unique perspective, enabling him to thoroughly assess both the scientific validity and commercial viability of potential investments. He is known for his ability to forge strong relationships with founders and management teams, acting as a trusted advisor throughout their growth journey.
While specific portfolio companies are often confidential or subject to change, Gregory Harriman has been instrumental in building a portfolio of innovative companies that have achieved significant milestones in drug development, medical technology advancement, and healthcare delivery. His contributions have helped numerous startups navigate the complex landscape of clinical trials, regulatory approvals, and market entry, ultimately bringing life-changing solutions to patients. Gregory Harriman's commitment to fostering innovation and his strategic acumen make him a key figure in the venture capital ecosystem, driving forward the mission of BioAdvance to support the next generation of life science leaders.
Gregory Harriman is a Partner at BioAdvance, a venture capital firm specializing in life science investments. He is responsible for identifying, evaluating, and supporting early-stage biotechnology and healthcare companies.
Gregory Harriman invests in early-stage life science companies, including those focused on drug discovery, novel therapeutics, medical devices, diagnostics, and digital health solutions. His focus is on innovative technologies with high growth potential.
Gregory Harriman works as a Partner at BioAdvance, a leading venture capital firm dedicated to advancing innovation in the life sciences sector.
